Status:

RECRUITING

Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration

Lead Sponsor:

Centre Georges Francois Leclerc

Conditions:

Localized Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Patients including of localized breast cancer will require chemotherapy treatment with epirubicin - cyclophosphamide (EC) followed by treatment with docetaxel or paclitaxel. In addition to this chemot...

Detailed Description

For this tudy : patients will be randomized to either : * with administration of peg-G-CSF (administration on D2) * with administration of G-CSF (administration on D4 to D7 or D8) This study aims to...

Eligibility Criteria

Inclusion

  • Women
  • Patient over 18 years old
  • Patient with histologically documented, non-metastatic breast cancer who must receive dense dose Epirubicin-Cyclophosphamide (EC) type treatment as part of neoadjuvant or adjuvant treatment
  • Patient to receive granulocyte growth factors (G-CSF or peg-G-CSF) as a preventive measure from the first cycle
  • Neutrophils \> 1,500 /mm3; platelets \> 100,000 /mm3
  • Written informed consent, dated and signed
  • For patients of childbearing age, effective means of contraception during treatment and up to 3 months after stopping treatment

Exclusion

  • Patient with a contraindication to treatment with anthracyclines
  • Patient already undergoing treatment with EC dense dose
  • Patient with a contraindication to treatment with G-CSF such as hypersensitivity to the active ingredient or to one of the excipients
  • Pregnant or breastfeeding women
  • Patient under guardianship or curatorship or subject to a protection regime for adults
  • Patient not affiliated to a social security scheme (beneficiary or beneficiary)

Key Trial Info

Start Date :

September 2 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 2 2025

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT05296317

Start Date

September 2 2022

End Date

October 2 2025

Last Update

February 29 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre Georges François Leclerc (CGFL)

Dijon, Bourgogne-Franche-Comté, France, 21000